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Abstract 
Background: Tumour‑derived microvesicles (TMVs) are important players in tumour progression, modulating 
biological activity of immune cells e.g. lymphocytes, monocytes and macrophages. This phenomenon is particularly 
interesting in the progression of colon cancer, as macrophages in this type of tumour are relevant for the recovery 
processes. In the present study, the role of colon cancer cell‑derived microvesicles in monocyte differentiation and 
activity profile (polarization) was investigated.
Methods: Monocyte‑derived macrophages (MDM) were differentiated in vitro in the presence of TMVs obtained 
from colon cancer: Caco‑2, SW620, LoVo or SW480 cell lines and analysed according to their morphology and biologi‑
cal functions, as defined by cytokine secretion, reactive oxygen intermediate (ROI) production and cytotoxic activity 
against respective colon cancer cells.
Results: Monocytes differentiated with TMVs exhibited morphological and phenotypical characteristics of mac‑
rophages. An early contact (beginning with the first day of the in vitro culture) of monocytes with TMVs resulted 
in increased IL‑10 secretion and only slightly elevated TNF release. Early, or prolonged contact resulted in low ROI 
production and low cytotoxicity against tumour cells. On the other hand, late contact of MDM with TMVs, stimulated 
MDM to significant TNF and IL‑12 secretion, ROI production and enhanced cytotoxicity against tumour cells in vitro. 
In addition, differences in MDM response to TMVs from different cell lines were observed (according to cytokine 
secretion, ROI production and cytotoxicity against tumour cells in vitro). Biological activity, STATs phosphorylation and 
microRNA profiling of MDMs indicated differences in their polarization/activation status which may suggest mixed 
polarization type M1/M2 with the predominance of proinflammatory cells after late contact with TMVs.
Conclusions: Macrophage activity (polarization status) may be regulated by contact with not only tumour cells but 
also with TMVs. Their final polarization status depends on the contact time, and probably on the vesicle “cargo”, as 
signified by the distinct impact of TMVs which enabled the switching of MDM maturation to regulatory macrophages.
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Background
Colorectal cancer is the third most common cancer and 
the fourth most frequent cause of cancer deaths world-
wide [1, 2]. This type of tumour occurs generally after 
the age of 50 and in most cases is sporadic, however, the 
occurrence of genetic or epigenetic causes along with 
the inflammatory microenvironment support colorec-
tal cancer development [3]. The infiltrating leukocytes, 
mainly monocytes, which give rise to macrophages, are 
the hallmarks of this process [4]. The majority of mac-
rophages infiltrating neoplastic tissue (TAM, tumour 
associated macrophages) have phenotype characteristics 
of M2 polarized cells, which are known to participate in 
Open Access
Journal of 
Translational Medicine
*Correspondence:  mibaj@cyf‑kr.edu.pl 
1 Department of Clinical Immunology, Institute of Peadiatrics, Medical 
College, Jagiellonian University, 265 Wielicka str., 30‑663 Cracow, Poland
Full list of author information is available at the end of the article
Page 2 of 15Baj‑Krzyworzeka et al. J Transl Med  (2016) 14:36 
each step of cancer progression including dissemination, 
seeding and metastasis formation [5]. The level of their 
infiltration is used as an independent prognostic factor 
in many tumour types [6]. However, it should be noted 
that in case of colorectal cancers, a strong macrophage 
infiltration does not necessarily correlate negatively with 
patients’ survival [4, 7, 8]. This may be associated with 
proinflammatory TAMs, which play an antitumour role, 
leading to a favourable prognosis [9]. Different biologi-
cal properties of macrophages could be associated with 
distinct factors (growth factors, cytokines etc.) in their 
microenvironment during the differentiation process [10]. 
The tumour microenvironment is a very complex system 
of cell to cell interplay complemented by cellular interac-
tions with the extracellular environment. Tumour cells are 
essential players in these processes, however, other factors 
should be also taken under consideration. One of the most 
intriguing factors are ubiquitous extracellular vesicles 
(EVs). During tumour progression, monocytes in blood, 
as well as macrophages in the tumour bed, are exposed 
to EVs released by nearby cells [11, 12] to body fluids [13, 
14]. EVs are defined as membrane fragments of various 
shapes released by cells during their lifespan. Using the 
size and origin criteria, EVs are classified into two groups: 
exosomes, which are smaller (30–100  nm), more homo-
geneous in size and released by the endosomal compart-
ment, and ectosomes, also known as microvesicles (MVs) 
[15], which are larger (0.1–1  μm) [16] and mainly origi-
nated from plasma membranes. EVs are also released by 
tumour cells, thus, impacting the activity of blood mono-
cytes and TAM in tumour bed [17]. Based on their cargo 
(proteins, growth factors, mRNA and microRNAs) EV are 
regarded as “messengers” [12–15], which may affect bio-
logical activity of macrophages. miRNAs deserve special 
attention as they may regulate all differentiation steps and 
change the activation status of macrophages [18]. In the 
present study, we asked whether TMVs released by colon 
cancer cell lines (with different growth potential) may 
influence monocyte differentiation, thus, affecting their 
activity/polarization status. In another words, we asked, 
if TMVs, as tumour “go-between” present in body fluids/
tumour environment, may direct/educate monocytes dur-
ing their differentiation. Our results indicate an important 
role of TMVs in this process and suggest that TMVs ori-
gin and the time of their “first contact” with monocytes/
macrophages are crucial for their ultimate activity and 
function.
Methods
Isolation of monocytes
Human peripheral blood mononuclear cells (PBMCs) 
were isolated from EDTA-blood of healthy donors by the 
Ficoll/Isopaque (Pharmacia, Uppsala, Sweden) density 
gradient centrifugation. Monocytes were separated from 
PBMCs by counter-flow centrifugal elutriation with the 
JE-6B elutriation system equipped with a 5 ml Sanderson 
separation chamber (Beckman-Coulter, Palo Alto, CA), 
as previously described [19]. Monocytes were suspended 
in RPMI 1640 culture medium (PAA Laboratories, Pas-
ching, Germany) with gentamycin (Sigma, St. Louis, 
MO) (25 μg/ml). Purity of monocytes was over 95 %, as 
judged by staining with anti-CD14 mAb (BD Biosciences 
Pharmingen, San Diego, CA) and flow cytometry analy-
sis (FACSCanto BD Biosciences Immunocytometry 
Systems, San Jose, CA). The study was approved by the 
local Jagiellonian University Ethical Committee (No. 
KBET/160/b/2011).
Isolation of TMVs
TMVs were obtained from the following human colon 
cancer cell lines: Caco-2, SW480, SW620 and LoVo as 
previously described [20]. The cell lines were a generous 
gift from prof. Caroline Dive (Paterson Institute for Can-
cer Research, The University of Manchester). Cell lines 
differed in malignancy potential as Caco-2 was described 
as poorly aggressive, SW480-with low metastatic ability, 
SW620-high metastatic ability and LoVo-undifferenti-
ated. Cells were cultured by bi-weekly passages in RPMI 
1640 (Caco-2 and LoVo) or DMEM (SW480 and SW620) 
(PAA) with 5  % FBS (foetal bovine serum, Biowest, 
Nuaille, France) centrifuged before the use at 50,000×g 
for bovine-derived MVs depletion. Cell lines were regu-
larly tested for Mycoplasma sp. contamination by using 
PCR-ELISA kit according to the manufacturer’s protocol 
(Roche, Mannheim, Germany). Supernatants from well-
grown cell cultures were collected, centrifuged at 2000×g 
for 20  min to remove cell debris and then centrifuged 
again at 50,000×g (RC28S, Sorvall, Newton, CT) for 1 h 
at 4 °C. Pellets were washed twice in PBS to remove FBS 
and finally resuspended in serum-free medium. Quanti-
fication of TMVs proteins was evaluated by the Bradford 
method (BioRad, Hercules, CA). TMVs were tested for 
endotoxin contamination by the Limulus test according 
to the manufacturer’s instruction (Charles River Labo-
ratories, Inc., Wilmington, MA) and stored at −20  °C 
until use. As an additional control for some experiments 
MVs from non-malignant urothelial cells HCV-29 were 
used. To simplify, TMVs were named according to their 
cell line origin e.g. TMVs released from Caco-2 as TMV-
Caco2, from LoVo-TMVLoVo, from SW480-TMVSW480, from 
SW620 as TMVSW620 and from HCV-29 as MVHCV.
Differentiation of monocytes to monocyte‑derived 
macrophages (MDM)
Blood monocytes were cultured for 7 days in 24-well low 
attachment plates (Corning Incorporated, Corning, NY) 
Page 3 of 15Baj‑Krzyworzeka et al. J Transl Med  (2016) 14:36 
at the density of 1×106/well at 37 °C, 5 % CO2 in humidi-
fied atmosphere. In the preliminary experiments, RPMI 
1640 medium supplemented with FBS (low in endotoxin 
and MV-depleted) was established as adequate for differ-
entiation of human monocytes to MDM. Also, the dose 
of TMVs (3 μg/ml) that had no impact on the viability of 
MDM (see below) was established during the prelimi-
nary experiments. TMVs (3  µg/ml) were added to the 
monocyte culture in three different combinations: (i) at 
day 0 (abbreviated as MDM + TMV0d), (ii) at days 0, 3, 
6 (MDM + TMV036d), (iii) at day 6 (MDM + TMV6d) 
(Fig. 1). After 3 days of culture, half of the medium was 
removed and replaced with freshly prepared one. Our 
previous results indicated that TMVs supplemented at 
day 0 were completely engulfed after 24  h, so the risk 
to remove them was unlikely [20]. Monocytes cultured 
alone (without TMVs) were used as a control (equivalent 
to M0 macrophages) [21] and defined as control MDM. 
In parallel, MDM were differentiated in the presence of 
GM-CSF (1000  U/ml, Immunotools GmbH, Friesoythe, 
Germany) or M-CSF (10  ng/ml, Peprotech, Princeton, 
NY) which have been described to induce an M1 and 
M2 like phenotype, respectively [21]. As an additional 
control MVHCV and fluorescent beads [0.4  μm Fluores-
brite Yellow Green (YG) carboxylate microspheres, Pol-
ysciences, Warrington, USA] were used, to check the 
impact of normal MVs and the engulfment process on 
MDM differentiation. After 7  day culture, cell viability 
was determined by Annexin V (BD Pharmingen) bind-
ing and TO-PRO-3 (Invitrogen, Waltham, MA) staining; 
only cells with viability above 95 % were used for further 
testing.
Morphology and phenotype of MDM
The morphology of macrophages was investigated daily 
by phase contrast microscopy (600× magnification) 
Olympus IX70 (Olympus Corp. PA). MDM morphology 
was assessed using cytospin slides stained for 3 min with 
the Wright’s dye (Merck, Darmstadt, Germany) at the last 
day of culture by light microscopy (Olympus BX51). Phe-
notype analysis was performed at day 7 using flow cytom-
etry. The following monoclonal antibodies (mAbs) were 
used: APC-labelled anti-CD14, FITC-labelled anti-CD33, 
-CD80, -CD15, PE-labelled anti-CD1a, -CD206, -CD86, 
-CD11b, PerCP-labelled anti-HLA-DR, PerCP-Cy5.5-
labelled anti-CD163, all from BD Pharmingen. Antibodies 
from R&D System: FITC-labelled anti-CD115 (MCSF-R), 
PE-labelled anti-CD36. For intracellular staining (CD68 
FITC) MDM were fixed with Cytofix and permeabilised 
with PermWash buffers, both from BD Pharmingen. 
CD68 staining was done using mAb from Dako Cyto-
mation (Glostrup, Denmark). Additionally, kinetics of 
CD206 expression was examined on a daily basis using 
flow cytometry. All antibodies were used in saturating 
Fig. 1 Scheme of experiments. Control MDM were obtained from human peripheral blood monocytes cultured for 7 days without growth 
factors. MDM + TMV0d were obtained from human peripheral blood monocytes supplemented at day 0 with appropriate TMVs. Similarly, 
MDM + TMV036d were exposed to TMVs at day 0, 3 and 6 and MDM + TMV6d only at day 6. All other culture conditions were the same
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concentrations with appropriate isotype-matched con-
trols. MDM were incubated with mAbs for 30 min at 4 °C, 
washed and then analysed in FACSCanto flow cytometer.
Cytokine secretion
Supernatants obtained on day  7 of the MDM culture 
were collected and the concentration of TNF, IL-10 and 
IL-12 was measured by the following matched mAbs 
pairs for ELISA (BD Pharmingen): for TNF-MAb1 
(capture) and MAb11 (detection), for IL-10-JES3-9d7 
(capture) and JES-12G8 (detection) and for IL-12p40/
p70-C8.3 (capture) and C8.6 (detection). Recombinant 
human cytokines (all from BD Pharmingen) were used 
as standards. Tests were performed according to the 
manufacturer’s protocol and results were obtained using 
the ELISA reader (BioTek Instruments, Vinooski, VT) at 
492 vs 630 nm wavelength. Detection level for TNF was 
20 pg/ml, and 10 pg/ml for IL-10, IL-12p40/p70.
microRNA (miR) expression
MDM differentiated in the presence of TMVs 
(TMVSW480, TMVSW620, TMVLoVo and TMVCaco2) were 
tested for miR expression profile. The total RNA was 
extracted from MDM, MDM +  TMVs (after 7  days of 
culture) and TMVs alone with mirVana™ miRNA Isola-
tion Kit (Ambion, Life Technologies, Austin, TX) accord-
ing to the manufacturer’s protocol. The first strand cDNA 
was obtained from the total RNA (400 ng) samples with 
Megaplex™ RT Primers (pool A and B, Applied Biosys-
tems, Foster City, CA). TaqMan Array Micro RNA Card 
Set v3.0 were used to detect expression of human miRs in 
preliminary studies. Real-time PCR was performed using 
the 7900HT System (Applied Biosystems). For miRs, 
which major differences in expression were detected in 
preliminary experiments (miR-9,-21,-155,-378,-511) indi-
vidual real-time PCRs (TaqMan Gene Expression Assays, 
Applied Biosystems) were performed. All experiments 
were performed three times and the PCR reactions were 
performed in triplicates using the 7300 Real-Time PCR 
System (Applied Biosystems). Reverse transcription was 
performed as described above (Megaplex RT primers 
pool A were used for miR-9,-21,-155,-511 and U6 as a 
control, Megaplex RT primers pool B were used for miR-
378 and U6). The fluorescent signals generated during 
the informative log-linear phase were used to calculate 
the relative amount of miR. U6 was used as a control for 
each PCR run and the miR expression was calculated as a 
fold difference from that of control MDM normalized by 
U6 results (2−ΔΔCT).
Determination of ROI production by flow cytometry
The intracellular production of ROI was measured by 
flow cytometry using oxidation-sensitive fluorescent 
probe hydroethidine (HE, Sigma). After 7  days, MDM 
expanded alone or in the presence of TMVs (added in 
the described regimen) were preincubated with 10  µM 
HE for 30 min and stimulated with phorbol 12-myristate 
13-acetate (4  µM PMA, Sigma) for 10  min, after which 
cells were washed and analysed immediately with FACS-
Canto flow cytometer.
Western blotting
To assess the master regulators in signalling processes 
that lead towards M1 (STAT1, STAT5) or M2 (STAT3, 
STAT6) differentiation Western blotting technique was 
employed. Monocytes were stimulated with TMVs for 
30′, 2 h, 4 h and 7 h at day 0 or day 6. After stimulation 
cells were lysed in M-PER lysing buffer (Pierce, Rock-
ford, IL) containing protease inhibitor cocktail (Roche). 
As a control unstimulated monocytes/MDM were used. 
The concentration of samples was measured using the 
Bradford kit (Bio-Rad) as per manufacturer’s instruction. 
20 µg of isolated protein was mixed with NuPAGE LDS 
Sample Buffer (4×) (Life Technologies, Carlsbad, CA) 
and NuPAGE Sample Reducing Agent (10×) (Life Tech-
nologies). Samples were heated (70 °C, 10 min) and elec-
trophoresed in 12 % polyacrylamide gel containing SDS. 
Next, electrophoresed samples were transferred onto 
the polyvinylidene fluoride membrane (Bio-Rad). Then, 
after blocking for 1 h at room temperature in Tris buff-
ered saline (TBS) with 0.1 % Tween-20 (Sigma, St. Louis, 
MO) and 1  % bovine serum albumin (BSA, Sigma) the 
membranes were incubated overnight at 4 °C with rabbit 
polyclonal antibodies: anti-phopspho-STAT1 (Tyr701), 
anti-phospho-STAT3 (Tyr705), anti-phospho-STAT5 
(Tyr694), anti-total STAT1, anti-total STAT3 and anti-
total STAT5 (all antibodies were purchased from Cell 
Signaling, Danvers, MA) diluted 1:1000. After incuba-
tion, membranes were washed in TBS supplemented 
with BSA and Tween-20 and incubated for 1 h at room 
temperature with secondary goat anti-rabbit antibody 
(dilution 1:2500) conjugated with horseradish peroxidase 
(Cell Signaling). The protein bands were visualized with 
the SuperSignal West Pico Chemiluminescence Substrate 
kit (Pierce) according to the manufacturer’s protocol and 
analysed with KODAK GEL LOGIC 1500 Digital Imaging 
System (KODAK, Rochester, NY).
Cytotoxicity assay
MDM cytotoxicity against tumour cells was tested, as 
described previously [21]. Briefly, after 7  day culture, 
MDM (5×104/well) grown alone or with TMVs were 
cocultured with the appropriate tumour cells (autolo-
gous) (2×104/well) for 48  h, after which the culture 
medium was removed and 100 μl of 1, 3-[4,5-dimetylth-
iazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, 
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2  mg/ml, Sigma) dye solution was added for 4  h. The 
experiment was repeated 5 times in triplicates. Formed 
formazan was extracted with isopropyl alcohol (Fluka 
Chemie AG, Buchs, Switzerland) containing 0,04  N 
HCl and its content was measured spectrophotometri-
cally (absorbance at 570 and 630  nm). The percentage 
of cytotoxicity was calculated according to the formula 
described previously [22].
Statistical analysis
Statistical analysis was performed by nonparametric 
Mann–Whitney test. Differences were considered signifi-
cant at p < 0.05.
Results
Monocytes in the presence of TMVs differentiate 
to macrophages
The presence of TMVs during the culture significantly 
changes morphology of MDM (Fig.  2). It was observed 
that MDM form clusters after exposure to TMVs. When 
cultures were monitored daily, the “spreading out” of 
MDM from the clusters was observed at day  5 (Fig.  2). 
Control MDM as well as MDM after beads engulfment 
did not form clusters. Control MDM after 7 day culture 
exhibited heterogeneous shapes including elongated 
and round cells (Fig.  2a). MDM generated in the pres-
ence of TMVSW620 from day 0 (MDM +  TMVSW620 0d) 
were heterogeneous in shape (Fig.  2b). Accountable 
“fried egg”-shaped cells next to clusters were observed 
when TMVSW620 were supplemented at the final dif-
ferentiation stage (MDM  +  TMVSW620 6d, Fig.  2b). 
MDM  +  TMVCaco2 0d were predominantly elongated 
(Fig.  2c). When TMVCaco2 were supplemented at day  6, 
MDM formed cluster-like structures (Fig.  2c). Similar 
pattern was observed for TMVSW480 (Fig. 2e), with “fried 
egg”-shaped cells more frequent at day  6. In the case 
of TMVLoVo, spindle-like cells were rare, while most of 
them resembled adherent macrophages (Fig.  2d), with 
“fried egg”-shaped morphology. In general, spindle-
like MDM, which resembled cells cultured with M-CSF 
(Fig. 2h) were more frequent when TMVs were added at 
0d. In contrast, MDM supplemented with TMV at day 6, 
looked similar to those differentiated with GM-CSF 
(Fig. 2h). MDM cultured with beads did not form cluster 
structures at all, and looked almost the same during the 
whole culture period (Fig. 2g). MDM supplemented with 
MVHCV were similar despite the time of the contact with 
MVHCV (Fig. 2f ).
MDM differentiated in the presence of TMVs were 
usually bigger with higher granularity (as judged by flow 
cytometry and light microscopy) (Fig. 3a, b).
Control MDM as well as MDM  +  TMVs expressed 
CD14 molecules in the absence of the typical markers of 
dendritic cells (CD1a) and granulocytes (CD15) (data not 
shown). However, MFI of CD14 was significantly higher 
in MDM  +  TMV6d (28,117  ±  9906) in comparison 
to other groups (11,804 ±  6422 for control MDM and 
12,096 ± 4991 for MDM + TMV0d). All MDM expressed 
macrophage-lineage marker CD68 (more than 90  %). 
Moreover, MDM were positive for CD11b and CD33 
(70 and 33  %, respectively). Table  1 presents expression 
of selected markers on MDM cultured alone or with 
TMVs. Differences in marker expression were observed 
in the case of CD206, CD36, CD80, CD86, and CD163 
after contact with particular TMVs and their significance 
was denoted with an asterisk (*p < 0.05, Table 1). Inter-
estingly, we observed a dynamic increase in CD206 posi-
tive cells during the first days after contact with TMVs 
(Fig.  4). The annexin V binding (less than 3  % of cells), 
and the TO-PRO-3 staining (below 2  %) were low (not 
shown). As an additional control, MDM cultured with 
MVHCV or fluorescent beads were used. No differences 
in the expression level of tested markers (as above) were 
observed between control MDM and MDM + MVHCV or 
MDM + beads (data not shown).
MDM + TMV0d and MDM + TMV6d differ in microRNA 
expression
Differences in expression of a number of miRs were 
observed including miR-9,-10a,-125a,-130a,-146a,-146b,-
15,-155,-21,-222,-223,-27a,-328,-378,-511,-1254. The 
most important miRs for differentiation and polarization 
process were analysed in subsequent experiments with 
TaqMan probes. We confirmed that MDM  +  TMV6d 
expressed more miR-155 than MDM  +  TMV0d 
(Fig. 5a). Upregulation of miR-378 was detected only in 
MDM + TMVLoVo6d and MDM + TMVSW4806d in com-
parison to MDM +  TMV0d (Fig.  5b). These two miRs 
are described to be associated with M1 polarization 
type. In parallel, we observed upregulation of miR-9 in 
all MDM + TMVs in comparison to control MDM, how-
ever expression of miR-9 in MDM + TMV0d was much 
higher than in MDM +  TMV6d. Significant differences 
were observed in the presence of TMVCaco2 (Fig.  5c). A 
similar trend was observed in miR-21 expression (higher 
in MDM +  TMV0d than in MDM +  TMV6d, Fig.  5d). 
miR-9 and miR-21 expression may suggest M2-like polar-
ization. Expression of miR-511 was significantly higher 
in MDM + TMV0d than in MDM + TMV6d which cor-
roborates with the surface expression of CD206 (Fig. 5e).
TMVs carry microRNA involved in macrophage 
differentiation
In parallel to miRs analysis in MDM, miRs expression 
in TMVs was determined, however, only miRs detected 
at CT below 31 were analysed (set arbitrarily, average 
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Fig. 2 Morphology of MDM (at day 3, 5 and 7) differentiated in the presence of medium alone (a) or TMVs: TMVSW620 (b), TMVCaco2 (c), TMVLoVo (d), 
TMVSW480 (e), MVHCV (f), beads (g) and growth factors (h). One representative experiment out of ten is presented
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CT presented in brackets). The TMVCaco2 carried miR: 
−106a (27, 92), −146b (30, 31), −155 (27, 82), −223 (30, 
15), and −378 (25, 31), TMVSW480-miR-106a (24, 88), 
−106b (29, 29), −146a (25, 83), −21 (28, 16), −222 (26, 
12), −223 (27, 62), −26a (28, 02), −378 (29, 23) and −9 
(30, 77), TMVSW620 −106a (24, 59), −146a (30, 06), −21 
(30, 28), −222 (25, 93), −223 (29, 13), TMVLoVo-miR-
106a (30, 76), −222 (29, 74), −328 (28, 70). miR-511 was 
not detected. Data are presented as a heat map (Fig. 5f ).
TMVs induce secretion of cytokines by MDM
Secretion of cytokines by MDM was tested after 
7  days of culture with/without TMVs (Fig.  6). In gen-
eral, MDM +  TMV6d secreted significantly more TNF 
(850 ±  303, 839 ±  199, 1781 ±  74, 1355 ±  559  pg/ml 
for TMVSW620, TMVCaco2, TMVLoVo and TMVSW480, 
respectively) than MDM  +  TMV0d (TMVs in order 
as above: 311 ± 62, 190 ± 114, 399 ± 119, 49 ± 24 pg/
ml) and control MDM (43 ±  13  pg/ml). Also secretion 
of IL-12 by MDM  +  TMV6d was elevated, except for 
MDM + TMVSW620 (340 ± 199, 863 ± 280, 741 ± 457 pg/
ml for TMVCaco2, TMVLoVo and TMVSW480 respectively) 
in comparison to MDM +  TMV0d (TMVs in order as 
above: 185 ±  68, 43 ±  24, 177 ±  151  pg/ml) and con-
trol MDM (26  ±  20  pg/ml). Interestingly, secretion of 
TNF and IL-12 was the lowest in MDM  +  TMV036d 
(except for TMVSW480). In the case of MDM + TMV0d, 
lower TNF secretion (see above) was accompanied by 
the increased secretion of IL-10 (558 ± 258, 491 ± 184, 
564  ±  181, 96  ±  57  pg/ml for TMVSW620, TMVCaco2, 
TMVLoVo and TMVSW480, respectively) whereas ele-
vated TNF (see above) and lower IL-10 levels (162 ± 65, 
54  ±  32, 476  ±  217, 33  ±  23  pg/ml, for TMVSW620, 
TMVCaco2, TMVLoVo and TMVSW480, respectively) were 
observed in MDM + TMV6d. MVHCV induced cytokines 
comparable with control MDM. Fluorescent beads did 
not induce TNF at all, while IL-10 and IL-12 secretion 
was similar to control MDM (data not shown).
MDM + TMV6d produce high amounts of ROI
MDM generated in the presence of TMVs produced ROI 
after PMA stimulation, however, the observed differ-
ences depended on the applied TMVs scheme. Significant 
increase of ROI production (mainly O2−) was observed 
only in MDM + TMV6d (22 + 9, 33 ± 14 and 37 ± 12 % 
of cells for TMVSW620, TMVLoVo and TMVSW480 
respectively) in comparison to the control MDM and 
MDM + TMV0d (13 ± 7). A similar profile of ROI pro-
duction was observed in three of the four tested TMVs 
(TMVSW480, TMVSW620, and TMVLoVo). TMVCaco2 did not 
induce ROI production by MDM (Fig. 7).
TMVs induce phosporylation of STAT1 and STAT3
To assess the polarization of MDM stimulated with 
TMVs, Western blot technique was employed to ana-
lyze STAT-1, 3, 5 and 6. Phosphorylation of STAT1, 3, 5 
and 6 was tested during the time interval of 30′–7 h. A 
weak phosphorylation signal for STAT1 in MDM 0d 
Fig. 3 MDM morphology analysed by cytospin slides after the Wright’s staining (a) and flow cytometry FSC/SSC dot plot (b) of MDM differentiated 
in the presence of TMVs. Left panel‑control, middle panel‑MDM + TMV0d, right panel‑MDM + TMV6d. (bar—50 µm). One representative example out 
of ten is presented
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and 6d stimulated with TMVLovo or TMVSW480 (Fig.  8a, 
c) for 7  h was detected. No phosphorylation of STAT1 
was observed after TMVCaco2 and TMVSW620 (Fig. 8b, d) 
stimulation. STAT3 was phosphorylated on tyrosine (but 
not serine) after stimulation (7 h) with any type of TMVs 
regardless of the time of contact (MDM 0d, MDM6d). 
STAT5 was phosporylated quickly (30′ stimulation) in 
all samples (including control MDM), while phospho-
rylation of STAT 6 was not detected (not shown). Data 
are presented as a representative (out of two perfomed) 
Western blot (Fig. 8).
TMVs change cytotoxic/cytostatic activity of MDM
Based on the obtained data, the cytotoxicity of control 
MDM in vitro against four tested colon cancer cell lines 
was app. 50  %. In general, MDM +  TMV6d were more 
cytotoxic against tumour cells (86 ± 31, 61 ± 26, 80 ± 17, 
84 ±  12  % of cells for TMVSW620, TMVCaco2, TMVLoVo, 
TMVSW480, respectively) than MDM + TMV0d (67 ± 19, 
55 ± 23, 49 ± 30, 51 ± 32 % of cells for TMVSW620, TMV-
Caco2, TMVLoVo, TMVSW480, respectively) and control 
MDM (56 ± 8, 46 ± 16, 50 ± 21, 54 ± 19 % of cells for 
SW620, Caco-2, LoVo and SW480 cells, respectively). 
We did not observe significant changes in cytotoxicity of 
MDM + TMV0d or MDM + TMV036d (Fig. 9) in com-
parison to control MDM.
Discussion
The present data show that TMVs released by colon can-
cer cells influence differentiation of blood monocytes to 
macrophages, resulting in their mixed polarization status 
(M1/M2) (Fig.  10). Phenotype and biological properties 
of the latter depend on the time of the “first” contact of 
monocytes with TMVs, as well as on the TMVs origin, 
which is related to their cargo (proteins, lipids etc.). To 
compare the impact of TMVs on monocyte differentia-
tion, four colon cancer cell lines with different growth 
potential were used. As a control, MVs from non-malig-
nant HCV-29 cell line were implemented into the study. 
Also, in our model three different time regimens of TMVs 
exposition were used to mimic contact of monocytes 
with TMVs: i) in the peripheral blood (MDM + TMV0d), 
ii) in the peripheral blood and later during e.g. extravasa-
tion (MDM + TMV036d), iii) at the final stage of matura-
tion (MDM + TMV6d) e.g. in the tumour bed.
It was previously reported that TMVs interact with 
human monocytes, leading to their activation [17]. The 
present study addressed the question whether TMVs may 
have an impact on monocyte differentiation and if so, 
what type of myeloid cells is generated as the result of this 
process. In the mouse model, tumour derived exosomes 
directed monocytes differentiation into myeloid-derived 
suppressor cells (MDSC), which were characterized by 
Fig. 4 Expression of CD206 on MDM cultured alone (upper panel) or with TMVLoVo0d (lower panel) after 24, 48, 96 h and 7 days. One representative 
experiment out of 6 performed is presented. Similar kinetics of CD206 expression was observed for other TMVs
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the expression of CD11b(+)Gr-1(+) markers [23]. More-
over, Valenti et  al. showed impaired differentiation of 
monocytes to dendritic cells in the presence of tumour 
exosomes and cytokines (GM-CSF, IL-4) [24]. This study 
shows that TMVs alone may impact differentiation of 
monocytes to macrophages, however, it should be kept 
in mind that we used a mixed population of vesicles, not 
just limited to exosomes. Depending on the time of the 
“first” contact between monocytes/MDM and TMVs 
(but not “normal” MV), differences in MDM morphol-
ogy, phenotype, cytokine secretion, ROI production and 
cytotoxicity against tumour cells in vitro were observed. 
We observed that TMVs present in the MDM culture 
induced transient cell cluster formation. The mechanism 
of this phenomenon is not clear, however, we suggest that 
this is related to hyaluronan, which is present in TMVs 
and MVs [25]. MDM differentiated in the presence of 
TMVs are bigger and more granular than control MDM. 
All of them showed intracellular expression of CD68 and 
surface expression of CD14, however, the highest CD14 
expression (marker of M1 cells [26]) was observed on 
MDM + TMV6d.
Expression of CD206 was significantly higher on 
MDM + TMV0d and MDM + TMV036d than on con-
trol MDM and MDM  +  TMV6d. Lower expression 
of HLA-DR on MDM +  TMV 6d was observed, but it 
was not significant. CD80 expression was elevated by 
all TMVs except for TMVSW620 (highly metastatic cell 
line). Expression of CD86 was significantly higher on 
MDM  +  TMV 6d. TMVSW480 decreased expression of 
Fig. 5 Expression of selected (involved in the MDM differentiation process) microRNAs in MDM + TMV0d and MDM + TMV6d vs control MDM 
(black line at level 1) presented as relative expression normalized to U6 (2−ΔΔCT): miR‑155 (a), miR‑378 (b), miR‑9 (c), miR‑21 (d), miR‑511 (e). Heat 
map of microRNA involved in MDM differentiation process detected in TMVs alone (f). Data from 3 independent experiments, performed in tripli‑
cates (mean ± SD) are shown. *p < 0.05
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Fig. 6 Secretion of cytokines (TNF, IL‑12, IL‑10) by MDM differentiated with TMVs. The supernatants were collected at day 7 and cytokines level was 
determined by ELISA method. Cytokine secretion by MDM culture with TMVSW620 (a), TMVCaco2 (b), TMVLoVo (c), TMVSW480 (d) is presented. Data from 6 
independent experiments (mean ± SD) are shown. *p < 0.05, **p < 0.001, ***p < 0.0001
Fig. 7 The intracellular production of ROI by MDM differentiated in 
the presence of TMVs. The level of ROI (mainly O2
−) production was 
determined by flow cytometry. MDM were stimulated with PMA in 
the presence of HE for 30 min. Percentage of positive cells was pre‑
sented (mean of six performed experiments). Data from 6 independ‑
ent experiments (mean ± SD) are shown. *p < 0.05
Fig. 8 Western‑blot analysis of STAT1, 3 and 5 phosphorylation. 
Monocytes isolated from blood of 2 donors were used: donor 1 
(a and c), donor 2 (b and d). a and b represents MDM0d, c and d 
represents MDM6d. Control MDM (1 and 4), MDM + TMVLoVo (2), 
MDM + TMVSW480 (3), MDM + TMVSW620 (5) MDM + TMVCaco2 (6). One 
representative experiment out of two performed is presented
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CD163 on MDM. No differences in CD115 (M-CSF R) 
expression were observed after contact with TMVs. We 
should stress out that these observation are specific for 
TMVs and not observed after contact with control MVs 
used in our study.
The phenotype of MDM  +  TMV6d (low HLA-DR, 
CD206, high CD86) combined with morphological fea-
tures may indicate TAM with mixed polarization. Simul-
taneous phosphorylation of STAT1 and STAT3, combined 
with the expression of miR-155 and miR-9 supports this 
hypothesis. The distinct expression of HLA-DR on TAM 
was also observed by others [27] and usually it was attrib-
uted to hypoxia conditions in the tumour bed [28]. Based 
on our findings, we suggest, that the HLA-DR expression 
may be also influenced by the previous stimulation/con-
tact with TMVs. In parallel, elevated expression of CD86, 
correlates with clinical data that most macrophages dis-
tributed along the invasive margin of colorectal carcinoma 
are CD86+ [29, 30]. Heterogeneity of TAM phenotype was 
described in different tumour types [31] and at different 
locations of the same tumour [32, 33] e.g. in colon cancer 
patients, CD80+, CD86+ and HLA-DR+ [34], as well as 
CD163+, CD86+, CCR2+ cells were described [7].
The elevated expression of CD206 (M2 marker) on 
MDM +  TMV0d and MDM +  TMV036d may indicate 
M2 polarization. Control MDM were grown in culture 
medium without growth factors to develop M0 pheno-
type [21], however, the elevated expression of CD206 may 
indicate spontaneous predominance of M2 over M1 phe-
notype in these cells [35]. The upregulation of the man-
nose receptor in tumour macrophages was accompanied 
by increase of miR-511-3p [36], which corroborates our 
Fig. 9 Cytotoxic/cytostatic activity of MDM against tumour cells. Monocytes were differentiated in the presence of TMVs and then cocultured with 
appropriate tumour cells for 48 h (a Caco‑2, b SW480, c SW620, d LoVo). Proliferation of cells was determined by MTT reduction assay. The results of 
five independent experiments are shown (mean ± SD). *p < 0.05
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data (Fig.  5e). Moreover, we observed dynamic increase 
of CD206 expression at day 1 of culture, which correlated 
with dynamic changes in different miR expression during 
the first day of differentiation [18].
Low expression of CD115 (M-CSFR) is rather a sign of 
non-M2 cells, as M-CSF directed differentiation towards 
M2 [37]. The decrease of CD115 on macrophages was 
previously observed by Rovida et al. and explained by its 
shedding by proteases from macrophages undergoing 
activation [38].
Different phenotype of macrophages infiltrating 
tumour site may allow to predict their activation status, 
which subsequently may anticipate their response to 
tumour. In fact, TAM phenotyping may be more inform-
ative than density/number of infiltrating cells for patient 
prognosis [33, 37].
In this study the activation of MDM was measured 
by cytokine secretion, ROI production and cytotoxic-
ity against tumour cells. Cytokine secretion by MDM 
and their phenotype, depended on time and frequency 
of the contact with TMVs and TMVs origin. The strong-
est secretion of TNF and IL-12 was observed when 
TMVs were added at the final stage of differentiation 
(MDM  +  TMV6d). In comparison, MDM  +  TMV0d 
released significantly more IL-10 than other types 
of MDM. MDM differentiated in the presence of 
TMVSW480 were the weakest producers of IL-10, while 
MDM  +  TMVLoVo6d and MDM  +  TMVSW4806d, pro-
duced the highest amounts of TNF, which may be 
related to their growth potential. It is of note that MDM 
differentiated after a prolonged contact with TMVs 
(MDM  +  TMV036d) secreted the lowest amounts 
of TNF and IL-12. This is in keeping with previously 
described deactivation of monocytes/macrophages by 
tumour cells [22], which may be observed also after 
TMVs contact, presumably via their hyaluronan compo-
nent [39].
The most potent ROI producers were MDM + TMV6d, 
but it seemed to be TMVs-origin dependent as TMV-
Caco2 did not induce production of ROI. MDM + TMV6d 
were more cytotoxic/cytostatic to tumour cells, most 
likely due to the cytotoxicity mediated by ROI and pro-
inflammatory cytokines. Our data corroborates with the 
observation that TAM isolated from spheroids of human 
colorectal cancer expressed antitumour potential prob-
ably via secretion of proinflammatory mediators [9].
The observed differences between MDM  +  TMV0d 
and MDM + TMV6d (early and late contact) may be due 
to the regulation of the differentiation process via e.g. 
microRNA. The first scenario is, that the fate of micro-
RNA in MDM is influenced not only by cytokines and 
nearby cells [18, 40] but also by TMVs present in the 
Fig. 10 Presentation of the hypothetical interactions of monocytes/macrophages with TMVs in the blood and in the tumour bed. Early contact of 
monocytes with TMVs resulting in M1/M2 mix polarization is schematically presented on the right. Late contact of macrophages with TMVs resulting 
in the induction of proinflammatory cells—left side. TMVs interactions with other immune cells as well as with tumour cells were omitted to simplify 
the scheme
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local environment. In keeping with this, we observed dif-
ferent miR expression profile in MDM  +  TMV0d and 
MDM + TMV6d. MDM after early contact with TMVs 
had upregulated miRs expression characteristic for 
M2-like cells (miR-21,-511,-9). The highest expression of 
these miRs was observed in the case of TMVCaco2, which 
induced differentiation of MDM with a lower proinflam-
matory capacity. MDM + TMV6d expressed higher lev-
els of miR-155 in comparison to MDM +  TMV0d and 
MDM control for all tested TMVs. MDM + TMVLoVo6d 
and MDM + TMVSW4806d expressed also more miR-378. 
Taken together, the miR profile may suggest predomi-
nance of M2 cells after early contact and more proin-
flamatory cells after late contact with TMVs. Morphology 
of MDM +  TMV6d (“fried egg”-shaped cells), and the 
cytokine secretion support the hypothesis of switch 
(at least in part of the cells) towards proinflammatory 
activity.
The second possibility, which complements the first 
one, is that miRNAs are carried by TMVs themselves. 
MVs were described before as safe transporters for miR-
NAs involved in regulation of cellular differentiation [41, 
42]. TMVs used in our experiments carried miR-106a, 
-146a, -155, -222, -223, -378 which are crucial for mac-
rophage differentiation and activation processes [43, 44], 
however, quantitative assessment of this phenomenon 
requires further confirmation. The direct transfer of miR 
cannot be excluded, except for miR-511 which was not 
detected in TMVs.
Our and others’ [45] results support the observation 
that TAM may have distinct properties, which do not fit 
perfectly the classical M1/M2 definition. We conclude 
that MDM differentiated in the presence of TMVs rep-
resent a mixed phenotype (M1/M2). We suggest that late 
contact with TMVs predisposes MDM to more proin-
flammatory activity. Hypothetical scenario is presented 
in Fig. 10. Furthermore, we suggest that biological activ-
ity of MDM is more important than their number and 
phenotype during tumour progression. Although, we 
do not have a formal proof, we suspect that removal of 
TMVs from blood in order to delay the first contact with 
monocytes, may improve macrophage activity against 
cancer. The idea is not new as Ichim et  al. proposed a 
physical approach in order to remove tumour exosomes 
from the body fluids of the cancer patients [46]. Also, the 
isolation of monocytes followed by their differentiation 
ex  vivo and “education” with TMVs may increase their 
anti-tumour potential. Again, the idea was already imple-
mented, but with dendritic cells [47].
Taken together, MDM differentiated in  vitro with 
TMVs fit the “colour wheel” classification of macrophage 
polarization as different “shades” of green [48], which we 
think, may be induced by TMVs.
Conclusions
TMVs modulated activity of monocytes and their differ-
entiation towards macrophages. The final polarization 
status of macrophages was dependent on TMVs origin 
and the time of contact with them. We suggest, that in 
the case of colon cancer, late contact of MDM with TMVs 
induced their mix polarization with significant proin-
flammatory potential.
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